Before vendor selection
Compare shortlisted AI vendors against scientific evidence, data requirements, workflow fit and expected R&D value.
Independent AI Vendor Evaluation for Pharma
AI vendor evaluation for pharma R&D decisions.
TranslAItion Partners helps pharma R&D leaders assess AI platforms before a pilot, license decision or strategic partnership, using independent scientific due diligence rather than vendor sales claims.
- No vendor affiliations
- No referral fees
- No conflicts of interest
The procurement risk
AI vendor demos are polished. Pharma R&D decisions need harder questions.
AI vendors in drug discovery, biomarker research, multi-omics analysis and clinical development often present strong claims: validated models, faster insights, better targets, lower costs and improved decision making. The problem is not that these claims are always wrong. The problem is that they are rarely neutral.
Before committing budget, data access, team capacity or strategic trust, pharma leaders need an independent view of whether the platform is scientifically credible, operationally realistic and valuable in their specific R&D environment.
When this matters
Use independent evaluation before the decision becomes expensive.
Before a pilot
Define what success should mean before the pilot starts, so the evaluation is based on real output rather than demo performance.
Before scaling
Assess whether early results can survive broader adoption, larger datasets, team handover and integration into existing R&D processes.
What we evaluate
An independent review across science, fit, risk and value.
Scientific validity
Are the claims supported by credible validation, publications, benchmarks or reproducible evidence?
Therapeutic context
Does the platform fit the disease area, biological question, modality, pipeline stage and decision workflow?
Data readiness
What data quality, format, volume, annotation and governance requirements does the vendor assume?
Implementation friction
What setup effort, training, integration, compliance review and internal adoption work will be required?
Cost-to-outcome value
How do license costs, hidden dependencies and team time compare with realistic scientific outcomes?
Decision risk
Where could the decision fail: overclaiming, vendor lock-in, weak validation, poor data fit or low adoption?
Evaluation process
From vendor shortlist to defensible recommendation.
The process is designed for leadership teams that need clarity before committing budget, data access or internal R&D capacity.
Decision context
Clarify the scientific problem, internal constraints, decision criteria and required level of confidence.
Evidence review
Review vendor claims, validation material, publications, benchmark data and known limitations.
Fit assessment
Map the platform against data readiness, workflow integration, adoption friction and therapeutic relevance.
Recommendation
Deliver an independent dossier with decision risks, go/no-go criteria and next-step guidance.
Deliverables
Practical outputs your team can use in a vendor decision.
Dossier
Independent Vendor Evaluation Dossier
A structured report covering scientific evidence, vendor claims, fit, risks, dependencies and recommendation logic.
Criteria
Pilot success criteria
Clear go/no-go criteria for testing whether the platform produces useful scientific output in your environment.
Briefing
Leadership decision briefing
A concise executive summary for scientific, innovation, procurement or investment stakeholders.
Why independence matters
The evaluator should not benefit from the vendor you choose.
TranslAItion Partners is not an AI platform vendor, implementation shop or broker. There are no referral fees, reseller agreements or vendor commissions. The only incentive is helping your team make a scientifically sound AI decision.
Principal
Dr. Rogier Reijmers
Immunologist · Translational Scientist · AI Evaluation Advisor
- PhD in Immunology with 20+ years of experience in translational research
- Background across academic and industry life-science environments
- Experience in grant review, scientific due diligence and technology evaluation
- Published researcher in immunology, oncology and translational medicine
FAQ
Common questions before evaluating an AI vendor.
When should a pharma team request an independent AI vendor evaluation?
Before a pilot, license decision or strategic AI partnership, especially when vendor claims need to be tested against your therapeutic area, dataset and R&D workflow.
Can this support procurement or investment decisions?
Yes. The evaluation is built to help scientific, innovation, procurement and leadership stakeholders understand evidence, risk and expected value before committing resources.
Do you receive referral fees from vendors?
No. TranslAItion Partners has no vendor affiliations, referral fees or broker commissions.
Need an independent view on an AI vendor?
Share the AI vendor, platform category or decision context. We will help you decide what needs to be evaluated before you commit.
All conversations are confidential. We respond within 24 hours.